GPRC5D and infection: In a cohort of 29 patients receiving GPRC5D-targeting BiAbs and 200 patients receiving BCMA-targeting BiAbs, the cumulative incidence of infection in the anti-GPRC5D group was 53% compared to 73% in the anti-BCMA cohort [36].